Value Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D

Inclusion Criteria: * Male/female Patients older 18 years old * Patients have signed written informed consent * Chronic Kidney Illness phase II-IV plus residual proteinuria \>0,5 grams/day (two or more consecutive occasions) and plus beta blockers treatment from AARS during al least 3 months. * Serum levels of calcifediol in the lack of level (15-30 ng/ml). Exclusion Criteria: * Bad control of high blood pressure (higher or same 180/110 mmHg) * Bad control of diabetes (HbA1c higher 9,5 in the last three months period) * Hypercalcemia (\<10,2 mg/dL) o hyperphosphatemia(\>5,5 mg/dL), CaxPO4\>50, hypercalciuria (urin Ca/Cr quotient \> 0,15) * Vitamin D treatment or any analogous * Hepatic failure ( AST o ALT \> 3 times higher than normal limit) * medical history of poor nutrient intestinal absorptions or chronic diarrhea * Active nephrolithiasis * Treatment with medication wich can change vitamin D metabolism (phenobarbital, phenytoin, rifampicin) * Participation in other Clinic Trial in 3 last months * Active Alcoholism * Neoplasia precedent (except cutaneous no melanoma) * Pregnant women or while breastfeeding * Vitamin D hypersensitivity or any its excipient hypersensitivity * Any other condition from Research